
    
      Peripheral T cell lymphoma patients of all subtypes according to WHO are treated with an
      induction of 6 cycles of CHOP-etoposide-14 (if below 60 years of age) oder CHOP-14. If at
      least a PR is reached, consolidation with alemtuzumab, total dose 133 mg, is given i.v.
    
  